LGALS3 and hypertensive disorder: Interference with Gal‐3 signalling by transgenic KO or specific Gal‐3 inhibitors blunts the fibrotic response and prevents LV deterioration in rodent models of pressure overload, hypertension and obesity‐related cardiac fibrosis (Yu et al, 2013; Calvier et al, 2015; Martínez‐Martínez et al, 2015).